Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).

被引：3
|
作者：
Dougherty, Brian
Ledermann, Jonathan A.
Lai, Zhongwu
Robertson, Jane D.
Ho, Tony
Hodgson, Darren R.
O'Connor, Mark J.
Fielding, Anitra
Hawryluk, Matthew J.
Brennan, Tim
Yelensky, Roman
Sun, James
Barrett, J. Carl
机构：
[1] AstraZeneca, Waltham, MA USA
[2] UCL, Inst Canc, London, England
[3] AstraZeneca, Macclesfield, Cheshire, England
[4] AstraZeneca, Wilmington, DE USA
[5] Fdn Med Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5536
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5536
引用
收藏
页数：1
相关论文
共 50 条
  • [31] IDENTIFYING THE PLATINUM-SENSITIVE HIGH GRADE SEROUS OVARIAN CANCER; THE SYNERGY BETWEEN HOMOLOGOUS RECOMBINATION AND NUCLEOTIDE EXCISION REPAIR
    Faraahi, Z. F.
    Tyagi, S.
    Gavrielides, N.
    Price, M.
    McCormick, A.
    Woodhouse, L.
    Crosbie, E.
    Edmondson, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1481 - 1481
  • [32] Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study
    Tashiro, Ryota
    Kawazoe, Hitoshi
    Mamishin, Kanako
    Seto, Keisuke
    Udagawa, Ryoko
    Saito, Yoshimasa
    Hashimoto, Hironobu
    Shimoi, Tatsunori
    Yonemori, Kan
    Yonemura, Masahito
    Terakado, Hiroyuki
    Nishimura, Takahiro
    Kawasaki, Toshikatsu
    Furukawa, Tetsuya
    Nakamura, Tomonori
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [33] Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial
    Korach, J.
    Freyer, G.
    Banerjee, S.
    Asher, R.
    Cosin, J.
    Oza, A. M.
    Poveda, A. M.
    Di Napoli, M.
    Scott, C.
    Lapresa, M.
    Heitz, F.
    Takehara, K.
    Sonke, G. S.
    Tjulandin, S.
    Kim, J-W.
    Hegg, R.
    Vergote, I. B.
    Turner, S.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer
    Tucker, Helen
    Charles, Zoe
    Robertson, Janet
    Adam, Jane
    LANCET ONCOLOGY, 2016, 17 (03): : 277 - 278
  • [35] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial (vol 15, pg 852, 2014)
    Ledermann, J.
    Harter, P.
    Gourley, C.
    LANCET ONCOLOGY, 2015, 16 (04): : E158 - E158
  • [36] Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors.
    Shapiro, Geoffrey I.
    Basu, Bristi
    El-Khoueiry, Anthony
    Postel-Vinay, Sophie
    Im, Seock-Ah
    Rha, Sun Young
    Friedman, Claire F.
    Italiano, Antoine
    Kim, Yong Man
    Lim, Myong Cheol
    Roux, Rene
    Liu, Joyce F.
    Sanai, Elhan
    Smith, Simon A.
    Smith, Claire
    El Farhi, Sarah
    Lau, Alan
    Lukashchuk, Natalia
    Dean, Emma
    Krebs, Matthew G.
    CANCER RESEARCH, 2022, 82 (12)
  • [37] MAINTENANCE OLAPARIB FOR BRCA-MUTATED OVARIAN CANCER (OC) PATIENTS IN 1ST LINE AND PLATINUM-SENSITIVE RELAPSED (PSR) SETTINGS: MAXIMIZING TREATMENT OPPORTUNITIES
    Poveda, A.
    Sackeyfio, A.
    Friedlander, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A133 - A133
  • [38] OLAPARIB TREATMENT IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER BY BRCA MUTATION AND HOMOLOGOUS RECOMBINATION DEFICIENCY STATUS: CHARACTERIZATION OF LONG-TERM/SHORT-TERM TREATMENT DURATION IN LIGHT
    Liu, Ying
    Mathews, Cara
    Simpkins, Fiona
    Cadoo, Karen
    Provencher, Diane
    Mccormick, Colleen
    Einaggar, Adam
    Altman, Alon
    Gilbert, Lucy
    Black, Destin
    Kabil, Nashwa
    Taylor, Rosie
    Barnicle, Alan
    Munley, Jiefen
    Aghajanian, Carol
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A156 - A157
  • [39] OREO PHASE IIIB TRIAL: OLAPARIB MAINTENANCE RETREATMENT IN PLATINUM-SENSITIVE, RELAPSED EPITHELIAL OVARIAN CANCER PATIENTS PREVIOUSLY TREATED WITH A PARP INHIBITOR (PARPI)
    Pujade-Lauraine, E.
    Colombo, N.
    Glasspool, R.
    Asselain, B.
    Huzarski, T.
    Korach, J.
    Marme, F.
    Mirza, M. R.
    Redondo, A.
    Scambia, G.
    Blakeley, C.
    Milner, A.
    Selle, F.
    Vergote, I.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1634 - 1635
  • [40] Evaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)
    Oza, A. M.
    Combe, P.
    Ledermann, J.
    Marschner, S.
    Amit, A.
    Huzarski, T.
    Lainez Milagro, N.
    Savarese, A.
    Scott, C.
    Nicoletto, M. O.
    Harter, P.
    Enomoto, T.
    Sonke, G. S.
    Kim, J-W.
    Vergote, I.
    Allen, A.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2017, 28
12345